Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes

Fig. 2

Disease activity score (DAS) (mean +/- 95% confidence intervals) over 4 months of treatment and mean initial change in DAS from baseline to 4 months (ΔDAS 0–4 months), separated by baseline serological status and breadth of autoantibody response. a, b DAS over time and ΔDAS 0–4 months separated by baseline autoantibody seropositivity based on anti-citrullinated protein 2 (anti-CCP2) IgG, rheumatoid factor (RF) IgM, or anti-carbamylated protein (anti-CarP) IgG positivity. Based on availability of antibody data, the total number of patients included in a and b is 472. c, d Within baseline seropositive patients, DAS over time and ΔDAS 0–4 months separated by the total number of isotypes present (anti-CCP2 IgG, IgM, IgA; RF IgM, IgA; and anti-CarP IgG, IgM, IgA). Due to the technical success rate of isotype measurements, and some seropositive patients testing negative upon re-measurement (see Additional file 1: Figure S1), the total number of patients included in c and d is 325. e, f Within patients seropositive at baseline, DAS over time and ΔDAS 0–4 months separated by the total number of anti-modified peptide antibodies (AMPAs) present (anti-CCP2 IgG, anti-CarP IgG, anti-citrullinated-vimentin 59-74 IgG, anti-citrullinated-fibrinogen β 36-52 IgG and α 27-43 IgG, anti-citrullinated-enolase 5-20 IgG, anti-acetylated-lysine IgG, and anti-acetylated-ornithine IgG). Thirty-eight patients were RF IgM positive but had no AMPAs (not shown). Due to the technical success rate of isotype measurements and some anti-CCP2 IgG and anti-CarP IgG positive patients testing negative upon re-measurement (see Additional file 1: Figure S1), the total number of patients included in e and f is 318. g Within baseline seropositive patients, ΔDAS 0–4 months separated by the number of isotypes present per antibody family and for the number of antibodies present to citrullinated or acetylated peptides. Reported p values are adjusted for multiple testing using Holmes-Bonferroni methods. ns, not significant (p ≥ 0.05); *p < 0.05; **p < 0.01, ***p < 0.001. Anti-cit. pept. Abs, anti-citrullinated peptide antibodies; Anti-acetyl. pept. Abs, anti-acetylated peptide antibodies

Back to article page